Skip to main content
. 2011 Nov 17;36(6):1411–1418. doi: 10.1007/s00268-011-1345-7

Table 2.

Survivin immunoreactivity in pancreatic endocrine tumors (n = 111)

Immunoreactivity No. of patients
Total Well-differentiated tumors Well-differentiated carcinomas Poorly differentiated carcinomas
Nuclear survivin
 <5% 80 (72%) 23 (92%) 44 (70%) 2 (29%)
 5–50% 21 (19%) 2 (8%) 12 (19%) 3 (43%)
 >50% 10 (9%) 7 (11%) 2 (29%)
Cytoplasmic survivin
 <5% 39 (35%) 4 (16%) 28 (44%) 3 (43%)
 5–50% 10 (9%) 6 (10%) 1 (14%)
 >50% 62 (56%) 21 (84%) 29 (46%) 3 (33%)

Total all specimens immunostained for survivin (n = 111). Well-differentiated tumors, Well-differentiated carcinomas, Poorly differentiated carcinomas: number of specimens immunostained for survivin when the WHO classification was available (n = 95)